Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Brain Neoplasms
/ diagnostic imaging
Chemoradiotherapy
Combined Modality Therapy
Cone-Beam Computed Tomography
Electric Stimulation Therapy
Glioblastoma
/ diagnostic imaging
Humans
Organs at Risk
/ radiation effects
Radiometry
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Radiotherapy, Intensity-Modulated
Scalp
/ radiation effects
Transducers
/ adverse effects
Dosimetry
Glioblastoma
Non-coplanar IMRT
TTFields
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
19 Apr 2020
19 Apr 2020
Historique:
received:
27
01
2020
accepted:
24
03
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
20
1
2021
Statut:
epublish
Résumé
Glioblastoma is a rapidly proliferating tumor. Patients bear an inferior prognosis with a median survival time of 14-16 months. Proliferation and repopulation are a major resistance promoting factor for conventionally fractionated radiotherapy. Tumor-Treating-Fields (TTFields) are an antimitotic modality applying low-intensity (1-3 V/cm), intermediate-frequency (100-300 kHz) alternating electric-fields. More recently interference of TTFields with DNA-damage-repair and synergistic effects with radiotherapy were reported in the preclinical setting. This study aims at examining the dosimetric consequences of TTFields applied during the course of radiochemotherapy. Cone-beam-computed-tomography (CBCT)-data from the first seven patients of the PriCoTTF-phase-I-trial were used in a predefined way for dosimetric verification and dose-accumulation of the non-coplanar-intensity-modulated-radiotherapy (IMRT)-treatment-plans as well as geometric analysis of the transducer-arrays by which TTFields are applied throughout the course of treatment. Transducer-array-position and contours were obtained from the low-dose CBCT's routinely made for image-guidance. Material-composition of the electrodes was determined and a respective Hounsfield-unit was assigned to the electrodes. After 6D-fusion with the planning-CT, the dose-distribution was recalculated using a Boltzmann-equation-solver (Acuros XB) and a Monte-Carlo-dose-calculation-engine. Overdosage in the scalp in comparison to the treatment plan without electrodes stayed below 8.5% of the prescribed dose in the first 2 mm below and also in deeper layers outside 1cm From a dosimetric point of view, dose deviations in the CTV due to transducer-arrays were not clinically significant in the first 7 patients and confirmed feasibility of combined adjuvant radiochemotherapy and concurrent TTFields. PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. DRKS00016667. Date of Registration in DRKS: 2019/02/26. Investigator Sponsored/Initiated Trial (IST/IIT): yes. Ethics Approval/Approval of the Ethics Committee: Approved. (leading) Ethics Committee Nr.: 18-8316-MF, Ethik-Kommission der Medizinischen. Fakultät der Universität Duisburg-Essen. EUDAMED-No. (for studies acc. to Medical Devices act): CIV-18-08-025247.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma is a rapidly proliferating tumor. Patients bear an inferior prognosis with a median survival time of 14-16 months. Proliferation and repopulation are a major resistance promoting factor for conventionally fractionated radiotherapy. Tumor-Treating-Fields (TTFields) are an antimitotic modality applying low-intensity (1-3 V/cm), intermediate-frequency (100-300 kHz) alternating electric-fields. More recently interference of TTFields with DNA-damage-repair and synergistic effects with radiotherapy were reported in the preclinical setting. This study aims at examining the dosimetric consequences of TTFields applied during the course of radiochemotherapy.
METHODS
METHODS
Cone-beam-computed-tomography (CBCT)-data from the first seven patients of the PriCoTTF-phase-I-trial were used in a predefined way for dosimetric verification and dose-accumulation of the non-coplanar-intensity-modulated-radiotherapy (IMRT)-treatment-plans as well as geometric analysis of the transducer-arrays by which TTFields are applied throughout the course of treatment. Transducer-array-position and contours were obtained from the low-dose CBCT's routinely made for image-guidance. Material-composition of the electrodes was determined and a respective Hounsfield-unit was assigned to the electrodes. After 6D-fusion with the planning-CT, the dose-distribution was recalculated using a Boltzmann-equation-solver (Acuros XB) and a Monte-Carlo-dose-calculation-engine.
RESULTS
RESULTS
Overdosage in the scalp in comparison to the treatment plan without electrodes stayed below 8.5% of the prescribed dose in the first 2 mm below and also in deeper layers outside 1cm
CONCLUSION
CONCLUSIONS
From a dosimetric point of view, dose deviations in the CTV due to transducer-arrays were not clinically significant in the first 7 patients and confirmed feasibility of combined adjuvant radiochemotherapy and concurrent TTFields. PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma.
DRKS-ID
UNASSIGNED
DRKS00016667. Date of Registration in DRKS: 2019/02/26. Investigator Sponsored/Initiated Trial (IST/IIT): yes. Ethics Approval/Approval of the Ethics Committee: Approved. (leading) Ethics Committee Nr.: 18-8316-MF, Ethik-Kommission der Medizinischen. Fakultät der Universität Duisburg-Essen. EUDAMED-No. (for studies acc. to Medical Devices act): CIV-18-08-025247.
Identifiants
pubmed: 32307022
doi: 10.1186/s13014-020-01521-7
pii: 10.1186/s13014-020-01521-7
pmc: PMC7168823
doi:
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
83Références
Med Phys. 1997 Jan;24(1):103-10
pubmed: 9029544
Radiother Oncol. 2016 Jan;118(1):35-42
pubmed: 26777122
Eur J Cancer. 2012 Sep;48(14):2192-202
pubmed: 22608262
Sci Rep. 2019 May 14;9(1):7362
pubmed: 31089145
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Front Oncol. 2018 Mar 13;8:51
pubmed: 29594036
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
Cancer. 2016 Jun 1;122(11):1718-27
pubmed: 26998740
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
J Clin Oncol. 2013 Nov 10;31(32):4085-91
pubmed: 24101040
Med Phys. 2018 Jun 16;:
pubmed: 29908062
Radiol Phys Technol. 2016 Jan;9(1):77-87
pubmed: 26493992
Radiat Oncol. 2017 Dec 29;12(1):206
pubmed: 29284495
Med Dosim. 2019 Spring;44(1):74-82
pubmed: 29598926
Radiother Oncol. 1992 Dec;25(4):251-60
pubmed: 1480770
Biomed Res Int. 2017;2017:8569328
pubmed: 29226151
Radiat Oncol. 2018 Feb 23;13(1):31
pubmed: 29471879
Strahlenther Onkol. 2014 Oct;190(10):925-32
pubmed: 24699988
Cell Death Dis. 2017 Mar 30;8(3):e2711
pubmed: 28358361
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
J Appl Clin Med Phys. 2015 Sep 08;16(5):142–158
pubmed: 26699322
J Appl Clin Med Phys. 2014 Sep 08;15(5):4912
pubmed: 25207577
Sci Rep. 2015 Dec 11;5:18046
pubmed: 26658786
Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):395-408
pubmed: 7751182
Oncotarget. 2016 Oct 4;7(40):65125-65136
pubmed: 27556184
Cell Death Dis. 2017 Apr 20;8(4):e2753
pubmed: 28425987
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Clin Neurosci. 2017 Aug;42:172-175
pubmed: 28427800
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7
pubmed: 17551011
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318